Latest Piperazines Stories
RALEIGH, N.C., Feb. 17, 2015 /PRNewswire/ -- Sprout Pharmaceuticals announced today that it has resubmitted a New Drug Application (NDA) to the U.S.
RnRMarketResearch.com adds "Otitis Media - Pipeline Review, H1 2015" report to its store. The report provides an overview of the Otitis Media's therapeutic pipeline. DALLAS, Feb.
LEXINGTON, Massachusetts, January 26, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the United States Food and Drug Administration (FDA) has granted
As off-label antipsychotic use is mounting so, too, is litigation associated with specific atypical antipsychotics Port Washington, New York (PRWEB) January
RALEIGH, N.C., Jan. 8, 2015 /PRNewswire/ -- Sprout Pharmaceuticals will participate in the 33rd Annual J.P. Morgan Healthcare Conference to be held January 12 - 15, 2015, in San Francisco.
DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S.
RALEIGH, N.C., Jan. 6, 2015 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Cindy Whitehead has been named CEO, effective immediately.
-- Expanded use of Gadavist is specific to detecting and visualizing areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in pediatric patients under the
WILMINGTON, Del., Dec. 19, 2014 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA(TM) (olaparib) capsules.
HPPI to commence Phase IIb study in first quarter 2015 of SUBA(TM)-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome TAMPA, Fla.
- An armed gangster.